Abstract
Sharing of equipment used to inject illicit drugs intravenously is a risk factor for human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). Systematic surveillance of HIV infection among intravenous drug users (IVDUs) in the United States is essential to monitor the HIV epidemic and to target and evaluate prevention programs for IVDUs and their partners. The most accessible segment of the largely covert population of IVDUs are those in drug treatment programs. In collaboration with State and local health departments and drug abuse treatment agencies, the Centers for Disease Control is conducting blinded (serologic test results not linked to identifiable persons) and nonblinded (in which clients voluntarily agree to participate) surveys of IVDUs entering drug treatment in 39 U.S. metropolitan areas. The same protocol is used in all participating drug treatment centers. Blinded surveys will be carried out annually to determine HIV seroprevalence rates in eligible IVDUs entering drug treatment and to monitor trends over time. Each year, nonblinded surveys of IVDUs entering drug treatment will assess self-reported drug use and sexual behaviors to help design educational interventions and to detect changes in behavior over time. This sentinel surveillance system, using a standardized methodology, will provide the best national and regional data available on the seroprevalence of HIV among IVDUs and the relationships of drug use, sexual behaviors, and HIV serologic status of IVDUs.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chaisson R. E., Bacchetti P., Osmond D., Brodie B., Sande M. A., Moss A. R. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989 Jan 27;261(4):561–565. [PubMed] [Google Scholar]
- Des Jarlais D. C., Friedman S. R., Novick D. M., Sotheran J. L., Thomas P., Yancovitz S. R., Mildvan D., Weber J., Kreek M. J., Maslansky R. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989 Feb 17;261(7):1008–1012. doi: 10.1001/jama.261.7.1008. [DOI] [PubMed] [Google Scholar]
- Dondero T. J., Jr, Pappaioanou M., Curran J. W. Monitoring the levels and trends of HIV infection: the Public Health Service's HIV surveillance program. Public Health Rep. 1988 May-Jun;103(3):213–220. [PMC free article] [PubMed] [Google Scholar]
- Hahn R. A., Onorato I. M., Jones T. S., Dougherty J. Prevalence of HIV infection among intravenous drug users in the United States. JAMA. 1989 May 12;261(18):2677–2684. [PubMed] [Google Scholar]
- Onorato I. M., Jones T. S., Forrester W. R. Using seroprevalence data in managing public health programs. Public Health Rep. 1990 Mar-Apr;105(2):163–166. [PMC free article] [PubMed] [Google Scholar]
- Onorato I. M., McCray E., Pappaioanou M., Johnson R., Aral S., Hardy A. M., Dondero T. J., Jr HIV seroprevalence surveys in sexually transmitted disease clinics. Public Health Rep. 1990 Mar-Apr;105(2):119–124. [PMC free article] [PubMed] [Google Scholar]
- Pappaioanou M., Dondero T. J., Jr, Petersen L. R., Onorato I. M., Sanchez C. D., Curran J. W. The family of HIV seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States. Public Health Rep. 1990 Mar-Apr;105(2):113–119. [PMC free article] [PubMed] [Google Scholar]
- Robertson J. R., Bucknall A. B., Welsby P. D., Roberts J. J., Inglis J. M., Peutherer J. F., Brettle R. P. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):527–529. doi: 10.1136/bmj.292.6519.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schalla W. O., Hearn T. L., Taylor R. N., Eavenson E., Valdiserri R. O., Essien J. D. CDC's Model Performance Evaluation Program: assessment of the quality of laboratory performance for HIV-1 antibody testing. Public Health Rep. 1990 Mar-Apr;105(2):167–171. [PMC free article] [PubMed] [Google Scholar]